In this study, using the Korean CNS cohort (N = 466) of the ASTRIS study, we assessed the intracranial activity of osimertinib in 89 patients with EGFR T790M-positive advanced NSCLC with available brain scan at baseline. Here, EGFR is linked to non-small cell lung carcinoma.